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Abstract
Background: A key physiological mechanism employed by multicellular organisms is apoptosis,
or programmed cell death. Apoptosis is triggered by the activation of caspases in response to both
extracellular (extrinsic) and intracellular (intrinsic) signals. The extrinsic and intrinsic pathways are
characterized by the formation of the death-inducing signaling complex (DISC) and the
apoptosome, respectively; both the DISC and the apoptosome are oligomers with complex
formation dynamics. Additionally, the extrinsic and intrinsic pathways are coupled through the
mitochondrial apoptosis-induced channel via the Bcl-2 family of proteins.
Results: A model of caspase activation is constructed and analyzed. The apoptosis signaling
network is simplified through modularization methodologies and equilibrium abstractions for three
functional modules. The mathematical model is composed of a system of ordinary differential
equations which is numerically solved. Multiple linear regression analysis investigates the role of
each module and reduced models are constructed to identify key contributions of the extrinsic and
intrinsic pathways in triggering apoptosis for different cell lines.
Conclusion: Through linear regression techniques, we identified the feedbacks, dissociation of
complexes, and negative regulators as the key components in apoptosis. The analysis and reduced
models for our model formulation reveal that the chosen cell lines predominately exhibit strong
extrinsic caspase, typical of type I cell, behavior. Furthermore, under the simplified model
framework, the selected cells lines exhibit different modes by which caspase activation may occur.
Finally the proposed modularized model of apoptosis may generalize behavior for additional cells
and tissues, specifically identifying and predicting components responsible for the transition from
type I to type II cell behavior.
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Apoptosis, or programmed cell death, is a highly
regulated cell death mechanism involved in many
physiological processes including development, elimina-
tion of damaged cells, and immune response [1-9].
Dysregulation of apoptosis is associated with pathologi-
cal conditions such as developmental defects, neurode-
generative disorders, autoimmune disorders, and
tumorigenesis [10-16]. The apoptotic pathway is char-
acterized by complex interactions of a large number of
molecular components which are involved in the
induction and execution of apoptosis. Although scien-
tists do not fully understand the entire pathway, key
characteristics have been identified which motivates
further study of this cellular process.
As summarized in Figure 1, apoptosis is a cell suicide
mechanism in which cell death is mediated by apoptotic
complexes along one of two pathways: the extrinsic
pathway (receptor mediated) via the death inducing
signaling complex (DISC), or the intrinsic pathway
(mitochondrial) via the apoptosome [1, 17-23].
The extrinsic initiator caspase (caspase-8) couples the
two pathways by initiating the mitochondrial apoptosis-
induced channel (MAC), leading to the activation of the
intrinsic pathway [24]. The subsequent cell death for
either pathway is executed through a cascade activation
of effector caspases (e.g., caspase-3) by initiator caspases
(e.g., caspase-8 and -9) and the amplification of death
signals implemented by several positive feedback loops
and inhibitors in the network [4, 15, 16, 25-28].
The DISC is formed by the ligation of transmembrane
death receptors such as Tumor Necrosis Factor (TNF)
Receptor family TNFR1 (CD95, Fas or APO-1) with
extracellular death ligands (such as FasL) which cluster
and bind to FADD adaptor proteins [21, 29-36]. The
ensuing complex recruits procaspase-8 through proxi-
mity-induced self-cleavage, which leads to the activation
of procaspase-8 to caspase-8 [37-39]. Caspase-8 then
activates downstream effector caspases such as caspase-3
to induce apoptosis [17].
The intrinsic pathway is activated by stimuli (such as
cellular stress or extrinsic pathway signals) inducing
mitochondrial membrane permeabilization, followed by
the formation of the apoptosome [40, 41]. The apopto-
some is a large caspase-activating complex [18-20] that
assembles in response to cytochrome c released from
mitochondria due to physical or chemical stress [22, 23].
Cytosolic cytochrome c activates Apaf-1 [42, 43] which
oligomerizes to form the apoptosome, a wheel-like
heptamer with angular symmetry [19, 44]. The apopto-
some recruits and activates procaspase-9 through pro-
teolytic cleavage [20]. Caspase-9 then catalyzes the
activation of procaspase-3 [45, 46].
These apoptotic pathways also include essential positive
and negative regulators. Negative regulators such as bifunc-
tional apoptosis inhibitor (BAR) or inhibitor of apoptosis
(XIAP) prevent caspase activation; conversely, Smac (DIA-
BLO)whichisaproteinreleasedwithcytochromecfromthe
mitochondria interacts with inhibitors of apoptosis to
promote caspase activation [47-50].
Both the extrinsic and intrinsic pathways may converge
at the destruction of the mitochondrial membrane. The
extrinsic pathway may activate the intrinsic pathway
through a mitochondrial apoptosis-induced channel
(MAC) of intracellular signals involving the Bcl-2 protein
family, which includes both pro-apoptotic (e.g., Bid,
tBid, Bax, Bad, Bcl-xs) and anti-apoptotic (e.g., Bcl-2, Bcl-
xL) members [51, 52].
Specifically, mitochondrial release of cytochrome c is
enhanced by truncated Bid [53-55]; upon cleavage by
caspase-8, Bid translocates to the outer mitochondrial
Figure 1
Extrinsic and intrinsic pathways to caspase-3
activation. Overview of pathways to caspase-3 activation.
Each separate gray region represent the three modules:
DISC (death-inducing signaling complex), MAC
(mitochondrial apoptosis-induced channel) and apoptosome.
Species and their symbols are: FasL (FasL), FasR (FasR), DISC
(DISC), procaspase-8 and caspase-8 (Casp8), bifunctional
apoptosis inhibitor (BAR), procaspase-3 and caspase-3
(Casp3), XIAP (XIAP), Bid and truncated Bid (Bid), Bax (Bax),
tBid - Bax2 complex (tBid - Bax2), Smac (Smac), Apaf-1 (Apaf),
cytochrome c (Cytc), apoptosome (Apop), procaspase-9 and
caspase-9 (Casp9). Arrows denote chemical conversions or
catalyzed reactions while hammerheads represent inhibition.
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interaction with Bax, leading to membrane pore forma-
tion by Bax oligomerization [24, 52, 56-59]. Corre-
sponding to the two apoptotic signaling pathways are
two types of cells [60, 61]: in response to death ligands,
cells that require DISC formation for apoptotic death are
primarily type I (e.g., T cells and thymocytes) while those
that release mitochondrial apoptogenic factors are
predominately type II cells (e.g., hepatocytes of Bcl-2
transgenic mice) [60-63].
Mathematical models have been employed recently to
gain further insights on the complex regulation of
caspase activation in apoptosis [57, 64-71]. Most of
these models focus on specific components of the full
apoptotic machinery. Models by Eissing et al. [65] and
Legewie et al. [66] emphasized only either the extrinsic or
intrinsic pathways, respectively. The model of Fusseneg-
ger et al. [67] implemented both pathways but did not
consider the coupling between them; however, Bagci et
al.[ 5 7 ] ,A l b e c ket al. [72] and Cui et al. [73] modeled the
mitochondrial apoptosis-induced channel. Stucki et al.
[68] modeled only the caspase-3 activation and degrada-
tion but none of the aforementioned models closely
track the upstream formation dynamics of the DISC and
the apoptosome, which have since been modeled in
detail by Lai and Jackson [74], and by Nakabayashi and
Sasaki [75], respectively. Hua et al. [69, 70] formulated
complete system models that incorporate the differences
in type I and II signaling as well as include more species,
such as Smac; however not all dynamics (e.g. feedbacks)
are included from previous component models [65, 66,
74, 75]. More recently, Okazaki et al.[ 7 1 ]f o r m u l a t e da
model based on Hua et al. of the phenotypic switch from
type I and type II apoptotic death, but their model does
not incorporate protein synthesis or degradation.
The primary focus of this work is to construct the simplest
model of caspase-3 activation featuring the oligomerization
kinetics of the DISC, mitochondrial apoptosis-induced
channel (MAC) and the apoptosome; the dynamics of the
extrinsic and intrinsic caspase subnetworks, as well as the
coupling between the extrinsic and intrinsic pathways. To
accomplish this, we constructed three independent func-
tional modules [76-79]. These are implemented for the
abstraction of oligomerization kinetics that simplify the full
system. Analysis of the system generates predictions of key
system components; furthermore, reduced models are
constructed to validate the analysis for different cell types.
Methods
Model formulation
The full reaction network of the model is built from
three component subnetworks (see Figure 1): the
extrinsic, coupling, and intrinsic subnetworks; and
three oligomerization modules (represented by gray
areas in Figure 1): the DISC, MAC, and apoptosome
modules. Each subnetwork captures a vital part of the
full apoptotic reaction network and borrows heavily
from previous work [57, 65, 66, 70, 71], while each
module abstracts the oligomerization kinetics of an
apoptotic complex to give a simplified net synthesis
function using steady-state results [74, 75].
The extrinsic subnetwork follows Eissing et al. [65] and
captures the dynamics of the extrinsic pathway. The
subnetwork contains the species FasL, FasR, DISC,
procaspase-8 (Casp8), caspase-8 (Casp8*), procaspase-
3 (Casp3), caspase-3 (Casp3*), XIAP, and BAR. The
subnetwork is driven by DISC, whose formation
dynamics from FasL and FasR are encapsulated by the
DISC module using the results of Lai and Jackson [74].
DISC induces the cleavage of Casp8 to Casp8*, which
then activates Casp3 to produce Casp3*. Positive feed-
back between Casp8* and Casp3* is provided by the
activation of Casp8 by Casp3*. XIAP and BAR act as
regulators by binding to Casp3* and Casp8*, respec-
tively. Furthermore, degradation of XIAP is enhanced by
Casp3*.
The extrinsic subnetwork can drive the intrinsic pathway
through the coupling subnetwork, which describes the
role of Casp8* in inducing mitochondrial membrane
permeabilization and triggering the release of cyto-
chrome c and Smac. The coupling subnetwork takes
after a combination of Bagci et al., Hua et al., and
Okazaki et al. [57, 70, 71], and contains the additional
species Bid, tBid, Bax, cytochrome c (mitochondrial,
Cytc; cytosolic Cytc*), and Smac (mitochondrial, Smac;
cytosolic, Smac*). The subnetwork receives input from
Casp8*, which cleaves Bid to produce tBid. Bax then
dimerizes with tBid to form tBid-Bax2,w h i c hi st a k e na s
a representation of the MAC that controls the release of
Cytc and Smac from the mitochondria to produce Cytc*
and Smac*, respectively; the formation dynamics of tBid-
Bax2 are abstracted in the MAC module using similar
methods as for the DISC module. Morever, Smac* acts as
a regulator by binding to XIAP.
The intrinsic subnetwork follows the intrinsic pathway
from the assembly of the apoptosome to the resulting
caspase interactions. The oligomerization of the apopto-
some is abstracted in the apoptosome module using the
results of Nakabayashi and Sasaki [75], while the
remainder of the subnetwork is simplified from Legewie
et al. [66]. Additional species contained in the subnet-
work include Apaf-1 (Apaf), apoptosome (Apop),
procaspase-9 (Casp9), and caspase-9 (Casp9*). The
subnetwork is driven by Cytc*, which binds to Apaf;
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cleaves Casp9 to produce Casp9*. As in the extrinsic
subnetwork, positive feedback exists between Casp9*
and Casp3*. Furthermore, Casp9* binds XIAP.
Constitutive synthesis and degradation rates are assumed
for all appropriate species.
Steady-state abstraction of oligomerization kinetics
The oligomerization kinetics of the DISC, MAC, and the
apoptosome are abstracted using steady-state results; this
abstraction is a demonstration of a simple technique for
modularization and model reduction. For an oligomer X
with intermediate structures X1,..., Xn and dynamics
dX
dt
fXX X X n
[]
([ ],[ ] ,...,[ ] ) [ ], =− 1 m
where f is the oligomerization rate function and μ the
degradation rate, use the steady-state approximation f ≈
fss µ [X]ss. This allows the modeling of only the final
complex and hence significant simplification of the
dynamical equations. Although the time dependence of
the oligomerization rate is neglected, information
regarding the long-term behavior is retained. For the
present application, take f =[ X]ss with proportionality
constant μ.
The abstractions for each of the DISC, MAC, and
apoptosome modules are described below, where the
notation is understood to apply only within each
module.
DISC module
The DISC oligomerization kinetics are simplified from
the crosslinking model [80-82] of Lai and Jackson [74]
and follow the reactions
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which has at most one positive root. Assume now that
FADD is in excess (see, e.g., [70, 71]) to obtain
[DISC]ss = c2,ss + c3,ss ≡ f (l0, r0; KD),
where it is assumed that both FasL-FasR2 and FasL-FasR3
can propagate the death signal [74]. Externally, in the
full reaction network, the oligomerization rate function
will be called as fDISC ([FasL]0,[ F a s R ] 0; KDISC). This
abstraction reduces the order of the system by four.
MAC module
The oligomerization kinetics of the MAC module are
assumed to follow a similar crosslinking model and
therefore obey the reactions
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With the analogous notation l ≡ [tBid], r ≡ [Bax], and ci ≡
[tBid-Baxi], the dynamics are
dl dt v
dr dt v v
dc dt v v
dc dt v
vk
/,
/,
/,
/,
=−
=− −
=−
=
⎧
⎨
⎪
⎪
⎩
⎪
⎪
=
1
12
11 2
22
1 2 f fr r
fr
lk c
vk c rk c
−
=−
⎧
⎨
⎪
⎩ ⎪
1
21 2 2
,
,
so
cl
r
KD
cl
r
KD
12
2
2 ,, ,, ss ss ss ss
ss ss =
⎛
⎝
⎜
⎞
⎠
⎟ =
⎛
⎝
⎜
⎞
⎠
⎟
Similar conservation relations then give that
Theoretical Biology and Medical Modelling 2008, 5:26 http://www.tbiomed.com/content/5/1/26
Page 4 of 15
(page number not for citation purposes)l
l
rK D
ss
ss
=
+
0
1 2 (/ )
with
rrr K r
lr K
Kl rK
D
D
DD
ss ss ss
32 2
0
00
00
0
22
22
++− =
=− +
=− +
⎧
⎨
⎩
ab
a
b
,
,
() ,
which again has at most one positive root. Therefore,
[tBid-Bax2]ss = c2,ss ≡ f (l0, r0; KD),
and externally this will be denoted by
fK tBid-Bax 22 0 ([ ],[ ] ; ) tBid Bax tBid Bax − , where the dynamical
concentration of tBid is used as input. The abstraction
reduces the order of the system by three.
Apoptosome module
The oligomerization kinetics of the apoptosome follow
the model of Nakabayashi and Sasaki [75] with no
dissociation, which considers bimolecular interactions of
the form
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Integration of this system until steady state over a range
of c0 generates a curve for x7 that may be accurately fit
with a piecewise exponential function
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where b1 and b2 may be fit for any prescribed l.
The apoptosome oligomerzation rate function is then
f(c0; l)=a0g(c0; l), and externally this is fApop([Cytc*]/
[Apaf]0; lApop). This abstraction reduces the order of the
system by eight.
Remarks on modularization
The steady-state profiles of the oligomerization kinetics
(as shown in Figure 2) are supported by the models that
motivated this simplification [74, 75] and experimen-
tally for tBid inducing a switch [49]. The abstraction
enables these module simplifications to operate as
inputs into the full dynamical system of apoptosis.
Model dynamical equations
The model species and reactions are summarized in
Tables 1 and 2. Reaction kinetics are described by mass
action, with the corresponding ordinary differential
equation (ODE) system given in Table 3. Initial
conditions to solve the ODEs for HeLa cells (from
[65]) and Jurkat T cells (based on [70, 71]), as well as
steady-state abstraction parameters, are given in Table 4,
where in particular the baseline value of [FasL]0 =2n M
corresponds to a dose which has been used to
experimentally induce apoptosis (see [70]).
Table 5 summarizes all model parameters (forward and
reverse reactions, synthesis and degradation rates and
parameters for the steady-state abstractions). Addition-
ally, a variant of the Jurkat T cell, denoted Jurkat T*, is
considered, which has the the same parameter values as
Jurkat T but with k2 = k5 = k12 = 0 following Hua et al.
and Okazaki et al.[ 7 0 ,7 1 ] .
The model ODEs are implemented in MATLAB R2007a
(The MathWorks, Inc., Natick, Mass., USA) and solved
using ode15s.
Regression analysis and model reduction
Integration of the model ODEs at baseline parameter
values (Table 5) gives the [Casp3*] time courses shown
in Figure 3. Both the HeLa and Jurkat T cells (the Jurkat
T* case will be addressed in the results) demonstrate a
characteristic behavior, whereby [Casp3*] stays low
initially, then quickly switches to a high state at some
threshold time.
Two quantitative descriptors are used to capture the form
of these time courses: the peak activation, the maximum
value of [Casp3*] attained over the time course; and the
activation time, the time at which this peak is achieved. To
determine the most significant aspects of the model
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performed with respect to these descriptors according to
the following procedure: For a given set of baseline
parameter values, we generate normally distributed
random parameters about the baseline with standard
deviation 5% of the baseline values. Then we simulate
the model at these parameters, compute the descriptors
and repeat this 100 times (the model has 54 parameters)
t oc o l l e c tas e to fs y n t h e t i cd a t a .
Since only local parameter perturbations have been
considered, linear relationship y =( 1X)b is assumed
between the standardized descriptors y (y being one of
[Casp3*]max and τ in standardized form) and the
standardized random parameters X,w h e r ee a c hr o wo f
X is a concatenation of the 54 model parameters in the
order given by Table 5. The relation b is solved by
multiple linear regression and large regression coeffi-
cients are taken to indicate essential components of the
network. This information is used to guide the formula-
tion of reduced models.
Results and discussion
Regression analyses and reduced models for FasL
induction
Regression analysis as described previously is performed
for baseline HeLa parameter values. Regression coeffi-
cients for each of the descriptors show isolated peaks,
indicating that only a small subset of the network is
responsible for the system behavior. Particularly, the
coefficients for the peak activation (r
2 = 0.9991) show
strong components only at the synthesis and degrada-
tion rates aCasp3 and μCasp3, which together control the
initial concentration [Casp3]0; evidently, this turns out
to largely be the case for all parameter sets considered
(not shown), so the peak activation will not be generally
further discussed. More interesting is the result for the
activation time (r
2 = 0.9958; see Figure 4a), which,
notably, shows that only the reactions of the extrinsic
subnetwork appear to be essential. Accordingly, a
reduced model (Figure 5a) consisting only of the
extrinsic subnetwork is formulated, and validation of
the reduction is given by comparison of the [Casp3*]
time courses between the full and reduced models.
Note that this result should be expected since the HeLa
cell was used in Eissing et al. [65] to study type I
apoptosis. Surprising, a similar analysis of the Jurkat T
cell, whose initial concentration parameters were used to
study type II apoptosis by Hua et al. and Okazaki et al.
[70, 71], leads to a similar reduction. The regression
coefficients (for the activation time; r
2 = 0.9903) are
shown in Figure 4b, with reduction shown in Figure 5b,
w h i c hi sj u s tt h a tf o rt h eH e L ac a s eb u tw i t hX I A P
omitted. It should be noted that the regression analysis
does not show a strong component at k2, perhaps due to
the corresponding reaction occurring at saturation;
therefore not sensitive to small perturbations.
Figure 2
Steady-state profiles of DISC, tBid-Bax2,a n d
apoptosome. Steady-state concentrations of DISC, tBid-
Bax2, and apoptosome, used for modularization of the DISC,
MAC, and apoptosome modules, respectively. (a) The
steady-state DISC concentration [DISC]ss as a function of the
initial death ligand ([FasL]0) and receptor ([FasR]0)
concentrations. (b) The steady-state tBid-Bax2 concentration
[tBid-Bax2]ss as a function of the initial Bax ([Bax]0)a n dt B i d
([tBid]0) concentrations. (c) The steady-state apoptosome
concentration [Apop]ss as a function of the initial Apaf-1
([Apaf]0)a n dc y t o c h r o m ec ([Cytc]0) concentrations.
Theoretical Biology and Medical Modelling 2008, 5:26 http://www.tbiomed.com/content/5/1/26
Page 6 of 15
(page number not for citation purposes)Nevertheless, simulations show the necessity to capture
the correct dynamics.
Review of the literature reveals that Hua et al.a n dO k a z a k i
et al. [70, 71] used the model variant denoted as Jurkat T*
in this work; for completeness, analysis of the Jurkat T* was
hence considered. While induction of the Jurkat T* cell by
baseline FasL still shows characteristic type I behavior
(Figure 4c, r
2 = 0.9846; see also the delayed activation in
Figure 3), a transition to type II apoptosis is observed for
low FasL ([FasL]0 = 0.01 nM), in accordance with the
transition reported Okazaki et al. [71]. This is to be
compared against the low FasL cases for the HeLa and
Jurkat T cells, which do not exhibit such a transition (not
shown). The activation time regression coefficients for the
Jurkat T* cell induced by low FasL case are shown in Figure
4d (r
2 = 0.9569), which in particular has strong
components at k7 and k8, which describe Bid truncation
Table 1: Species description, synthesis and degradation rates for the model equations
Species Description Synthesis rate (nM/s) Degradation rate (s
-1)
DISC DISC 8.807 × 10
-3
Casp8 procaspase-8 adjusted 6.5 × 10
-5 [65]
Casp8* caspase-8 9.667 × 10
-5 [65]
Casp3 procaspase-3 adjusted 6.5 × 10
-5 [65]
Casp3* caspase-3 9.667 × 10
-5 [65]
XIAP XIAP adjusted 1.933 × 10
-4 [65]
Casp3*-XIAP Casp3*-XIAP complex 2.883 × 10
-4 [65]
BAR BAR 1.111 × 10
-3 ([BAR]0 = 66.67 nM [65]) 1.667 × 10
-5 [65]
Casp8*-BAR Casp8*-BAR complex 1.933 × 10
-4 [65]
Bid Bid 4.168 × 10
-4 ([Bid]0 = 25 nM [70, 71]) 1.667 × 10
-5 (μBAR)
tBid truncated Bid 1.667 × 10
-5 (μBid)
tBid-Bax2 tBid-Bax2 complex 0.0264
Cytc cytochrome c (mitochondrial) 10
-3 ([Cytc]0 = 100 nM [70, 71]) 10
-5
Cytc* cytochrome c (cytosolic) 10
-5
Smac Smac (mitochondrial) 0.0167 ([Smac]0 = 100 nM [70, 71]) 1.667 × 10
-5 (μBAR)
Smac* Smac (cytosolic) 1.667 × 10
-5 (μSmac)
Smac*-XIAP Smac-XIAP complex 1.933 × 10
-4 (μCasp8*-BAR)
Apop apoptosome 1.487 × 10
-5
Casp9 procaspase-9 1.3 × 10
-3 ([Casp9]0 = 20 nM [70, 71]) 6.5 × 10
-5 (μCasp8)
Casp9* caspase-9 9.667 × 10
-5 (μCasp8*)
Casp9*-XIAP Casp9*-XIAP complex 2.883 × 10
-4 (μCasp3*-XIAP)
Model species and description are given. In the model, synthesis and degradation rates are given for the model system and labeled a and μ,
respectively.
Table 2: Reactions for the model equations
Number Reaction Forward rate (nM
-1 s
-1) Reverse rate (s
-1)
DISC (FasL, FasR) Æ DISC fDISC
1D I S C + C a s p 8 Æ DISC + Casp8* 10
-4 (k2)
2 Casp3* + Casp8 Æ Casp3* + Casp8* 10
-4 [65]
3 Casp8* + Casp3 Æ Casp8* + Casp3* 5.8 × 10
-4 [65]
4 Casp3* + XIAP ⇌ Casp3*-XIAP 3 × 10
-3 [65] 0.035 [65]
5 Casp3* + XIAP Æ Casp3* 3 × 10
-3 [65]
6 Casp8* + BAR ⇌ Casp8*-BAR 5 × 10
-3 [65] 0.035 [65]
7 Casp8* + Bid Æ C a s p 8 *+t B i d 5×1 0
-4 (est. [70, 71])
tBid-Bax2 (tBid, Bax) Æ tBid-Bax2 ftBid-Bax 2
8 tBid-Bax2 +C y t c Æ tBid-Bax2 +C y t c*1 0
-3 [70, 71]
9 tBid-Bax2 +S m a cÆ tBid-Bax2 +S m a c * 1 0
-3 [70, 71]
10 Smac* + XIAP ⇌ Smac*-XIAP 7 × 10
-3 [70, 71] 2.21 × 10
-3 [70, 71]
Apop (Cytc*; Apaf) Æ Apop fApop
11 Apop + Casp9 Æ Apop + Casp9* 2 × 10
-4 (est. [66])
12 Casp3* + Casp9 Æ Casp3* + Casp9* 2 × 10
-4 [66]
13 Casp9* + Casp3 Æ Casp9* + Casp3* 5 × 10
-5 [66]
14 Casp9* + XIAP ⇌ Casp9*-XIAP 1.06 × 10
-4 [70, 71] 10
-3 [70, 71]
Each reaction described highlights whether the reaction is a forward or reversible reaction by the arrows. The rates are provided from previous
work. Reaction are illustrated in Figure 1.
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(page number not for citation purposes)and the release of Cytc. Moreover, the peak activation
regression coefficients (r
2 = 0.9972, not shown) exhibit a
strong contribution by aSmac. The reduced model
(Figure 5c) is correspondingly dominated by the intrinsic
pathway; indeed, there is no direct interaction between
Casp8 and Casp3 at all. Furthermore, as implicated by the
synthesis rate of its inactive form, Smac*, and correspond-
ingly its target XIAP, plays a vital role in achieving the
correct activation level, which in particular illustrates the
critical role of the shared-inhibitor motif in apoptosis as
discussed by Legewie et al. [66].
Regression analyses and reduced models for
mitochondrial apoptosis
The behavior of the system pathways under mitochon-
drial apoptosis can also be studied. Cell stressors that
cause the depolarization and permeabilization of the
mitochondrial membrane are functionally represented in
the model by an input [tBid]0 =2 5n M( n o w[ F a s L ] 0 =
0). As for the FasL case, peak activation regression
coefficients for the cases considered below are domi-
nated by aCasp3 and μCasp3; therefore, will not be further
discussed.
Performing the regression analysis on the HeLa cell
induced by tBid produces the activation time regression
coefficients shown in Figure 4e (r
2 = 0.9705). Strong
components corresponding to the reactions of the
intrinsic subnetwork are observed; interestingly, the
system behavior is sensitive to several extrinsic reactions
as well. The model reduction is shown in Figure 6a,
which demonstrates that the extrinsic caspase feedback
Table 3: Ordinary differential equation system for the model
Differential equations Reaction velocities
d [DISC]/dt = μDISC(fDISC([FasL]0,[ F a s R ] 0; KDISC) - [DISC]) v1 = k1 [DISC] [Casp8]
d [Casp8]/dt =- v1 - v2 + aCasp8 - μCasp8 [Casp8] v2 = k2 [Casp3*] [Casp8]
d [Casp8*]/dt = v1 + v2 - v6 - μCasp8* [Casp8*] v3 = k3 [Casp8*] [Casp3]
d [Casp3]/dt =- v3 - v13 + aCasp3 - μCasp3 [Casp3] v4 = k4 [Casp3*] [XIAP] - k-4 [Casp3*-XIAP]
d [Casp3*]/dt = v3 - v4 + v13 - μCasp3* [Casp3*] v5 = k5 [Casp3*] [XIAP]
d [XIAP]/dt =- v4 - v5 - v10 - v14 + aXIAP - μXIAP [XIAP] v6 = k6 [Casp8*] [BAR] - k-6 [Casp8*-BAR]
d [Casp3*-XIAP]/dt = v4 - μCasp3*-XIAP [Casp3*-XIAP] v7 = k7 [Casp8*] [Bid]
d [BAR]/dt =- v6 + aBAR - μBAR [BAR] v8 = k8 [tBid-Bax2][ C y t c]
d [Casp8*-BAR]/dt = v6 - μCasp8*-BAR [Casp8*-BAR] v9 = k9 [tBid-Bax2][ S m a c ]
d [Bid]/dt =- v7 + aBid - μBid [Bid] v10 = k10 [Smac*] [XIAP] - k-10 [Smac*-XIAP]
d [tBid]/dt = v7 - μtBid [tBid] v11 = k11 [Apop] [Casp9]
d [tBid-Bax2]/dt = mtBid-Bax 2 v12 = k12 [Casp3*] [Casp9]
( ftBid-Bax 2 ([tBid], [Bax]0 ; K tBid-Bax 2 ) - [tBid-Bax2]) v13 = k13 [Casp9*] [Casp3]
d [Cytc]/dt =- v8 + aCytc - μCytc [Cytc] v14 = k14 [Casp9*] [XIAP] - k-14 [Casp9*-XIAP]
d [Cytc*]/dt = v8 - μ Cytc*[ C y t c*]
d [Smac]/dt =- v9 + aSmac - μSmac [Smac]
d [Smac*]/dt = v9 - v10 - μSmac* [Smac*]
d [Smac*-XIAP]/dt = v10 - μSmac*-XIAP [Smac*-XIAP]
d [Apop]/dt = μApop(fApop([Cytc*]/[Apaf]0 ; lApop) - [Apop])
d [Casp9]/dt =- v11 - v12 + aCasp9 - μCasp9 [Casp9]
d [Casp9*]/dt = v11 + v12 - v14 - μCasp9* [Casp9*]
d [Casp9*-XIAP] = v14 - μCasp9*-XIAP [Casp9*-XIAP]
Ordinary differential equations for the full system are given in the left hand column. Corresponding reaction velocities use mass-action kinetics are
found in the right hand column.
Table 4: Initial conditions for the model variables and oligomerization parameters
Initial concentration (nM)
Species HeLa Jurkat T Parameter Value
Casp8 216.67 [65] 33.33 [70, 71] [FasL]0 2 nM [70, 71]
Casp3 35 [65] 200 [70, 71] [FasR]0 10 nM [70, 71]
XIAP 66.67 [65] 30 [70, 71] KDISC 1.032 nM [70, 71]
BAR 66.67 [65] 66.67 [65] [Bax]0 83.33 nM [70, 71]
Bid 25 [70, 71] 25 [70, 71] K tBid-Bax 2 100 nM [70, 71]
Cytc 100 [70, 71] 100 [70, 71] [Apaf]0 100 nM [70, 71]
Smac 100 [70, 71] 100 [70, 71] lApop 1 [75]
Casp9 20 [70, 71] 20 [70, 71]
Initial conditions of model variables are given. Some species initial conditions differ between HeLa or Jurkat T cell type. Parameters and values are
given for steady-state oligomerization modules.
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(page number not for citation purposes)between Casp8 and Casp3 is essential to capturing the
correct dynamics (compare the time course with k2 =0 ) .
Thus, the HeLa cell displays an apoptotic mechanism that
involves the intrinsic pathway triggering the extrinsic
pathway. Furthermore, the role of Smac* as an indirect
activator of Casp3 through the sequestration of XIAP is
recovered. Although Casp9* possesses a similar seques-
tration ability, the analysisreveals that the primary role of
Casp9* is through direct activation of Casp3.
Analysis of the Jurkat T cell induced by tBid gives similar
results (Figure 4f, r
2 = 0.9879; reduced model not shown),
though the magnitude of the regression coefficient of k13,
which describes the activation of Casp3 by Casp9*, is larger
than in the HeLa case, suggesting a stronger role for the
intrinsic caspase. For completeness, the Jurkat T* cell is
induced by tBid is also considered. The activation time
regression coefficients are shown in Figure 4g. In this case,
the fit is relatively poor (r
2 = 0.8873) and some parameters
are selected in error (e.g., k1, which has no effect on the
system by construction; also note the larger number of
significant components). Nevertheless, the regression
serves to guide the model reduction, which in this
case required manual correction. The reduced model
(Figure 6b) reveals a purely intrinsic mechanism of caspase
activation. Similarly to the HeLa and Jurkat T cells, the
sequestration of XIAP by Smac* is essential, while that by
Casp9* may be neglected.
Although the peak activation for each of the HeLa, Jurkat T,
and Jurkat T* cells is essentially identical to that obtained
under FasL induction, the activation time shows a
significant increase (factor increase of 2.1457, HeLa;
1.3003, Jurkat T; 1.9920, Jurkat T*). This is in general
agreement with experimental evidence that caspase activa-
tion through the intrinsicpathway isdelayed relative tothat
through the extrinsic pathway [62].
Table 5: Summary of all rates and parameters for the system
Forward rate Reverse rate Synthesis rate Degradation rate Parameter
1 k1 15 k-4 19 aCasp8 27 μDISC 48 [FasL]0
2 K2 16 k-6 20 aCasp3 28 μCasp8 49 [FasR]0
3 k3 17 k-10 21 aXIAP 29 μCasp8* 50 KDISC
4 k4 18 k-14 22 aBAR 30 μCasp3 51 [Bax]0
5 k5 23 aBid 31 μCasp3* 52 K tBid-Bax 2
6 k6 24 aCytc 32 μXIAP 53 [Apaf]0
7 k7 25 aSmac 33 μCasp3*-XIAP 54 lApop
8 k8 26 aCasp9 34 μBAR
9 K9 35 μCasp8*-BAR
10 k10 36 μBid
11 k11 37 μtBid
12 k12 38 mtBid-Bax 2
13 k13 39 μCytc
14 K14 40 μCytc*
41 μSmac
42 μSmac*
43 μSmac*-XIAP
44 μApop
45 μCasp9
46 μCasp9*
47 μCasp9*-XIAP
The counter on the left hand columns totals the 54 model rates and parameters for the full system. Each subscript for k, a and μ corresponds to its
reaction number. The final column are the parameters used in the abstraction of oligomerization kinetics for the three modules.
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Figure 3
Caspase-3 time course results.T i m ec o u r s eo fc a s p a s e - 3
activation ([Casp3*]) in HeLa and Jurkat T cells represented
by solid and dashed lines, respectively. The time course for a
modification of the Jurkat T cell with k2 = k5 = k12 = 0 based
on the formulation of Hua et al. and Okazaki et al. [70, 71] is
denoted Jurkat T* and represented by the dotted line.
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In the preceding cases considered, type II apoptosis was
observed only for the Jurkat T* cell under low FasL
induction. This may be unsatisfactory since the Jurkat T*
cell omits caspase feedback interactions which suggest
potentially questionable biological relevance. Thus, a
natural idea is to determine whether parameters leading to
type II apoptosis may be predicted for the full reaction
network rather than resorting to the Jurkat T* formulation.
An attempt to use the regression analysis for this task was
made based on the idea of performing regression with
respect to differences in the peak activation and in the
activation times between a given parameter set and the
corresponding set with k7 = 0 (no Bid truncation, i.e., no
extrinsic-intrinsic coupling). The intuition in this
Figure 4
Regression analysis of apoptosis under various
conditions. Activation time regression coefficients for
sample model cases. The activation time is defined as the
time at which the peak caspase-3 concentration over the
time course occurs. The regression coefficients are ordered
by their parameter indices as shown in Table 5. Induction by
FasL ([FasL]0 = 2 nM unless noted) corresponds to receptor-
mediated apoptosis, while induction by tBid corresponds to
mitochondrial apoptosis ([tBid]0 =2 5n Ma n d[ F a s L ] 0 =0
unless otherwise noted). (a) HeLa cell induced by FasL (r
2 =
0.9958). (b) Jurkat T cell induced by FasL (r
2 = 0.9903). (c)
Jurkat T* cell induced by FasL (r
2 = 0.9846). (d) Jurkat T* cell
induced by low FasL ([FasL]0 =0 . 0 1n M ;r
2 = 0.9569). (e)
HeLa cell induced by tBid (r
2 = 0.9705). (f) Jurkat T cell
induced by tBid (r
2 = 0.9879). (g) Jurkat T* cell induced by
tBid (r
2 = 0.8873). (h) Predicted type II apoptosis cell
parameters (k-4 = k-6 =1 0
-3 s
-1,[ X I A P ] 0 = 200 nM, [FasR]0 =
1 nM) induced by FasL (r
2 = 0.9264).
Figure 5
Reduced models under induction by FasL. Reduced
models of apoptosis under induction by FasL (receptor-
mediated apoptosis; [FasL]0 = 2 nM unless noted), with time
course validations. In (a) and (c), the time courses of the full
and reduced models essentially overlap. (a) HeLa cell induced
by FasL. (b) Jurkat T cell induced by FasL. (c) Jurkat T* cell
induced by low FasL ([FasL]0 =0 . 0 1n M ) .
Figure 6
Reduced models by tBid. Reduced models of apoptosis
under induction by tBid (mitochondrial apoptosis; [tBid] = 25
nM and [FasL]0 = 0), with time course validations. In both
c a s e s ,t h et i m ec o u r s e so ft h ef u l la n dr e d u c e dm o d e l s
essentially overlap. (a) HeLa cell induced by tBid. (b) Jurkat
T* cell induced by tBid.
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(page number not for citation purposes)analysis is that strong regression coefficients (assuming
the modified descriptors are taken with the appropriate
sign) now select parameters whose increase may effect a
transition from type I to type II behavior. Furthermore,
the parameters randomly perturbed are now restricted to
only the synthesis and degradation rates, and to [FasL]0,
[FasR]0,[ B a x ] 0,a n d[ A p a f ] 0, i.e., the parameters that
control only the initial concentration, referred to as cell-
specific parameters, as these are presumably the only
parameters which may vary between different cell types.
Unfortunately, the regression coefficients for this analy-
sis give poor fits (0.3884 ≤ r
2 ≤ 0.7714 for the activation
time difference) for the cases considered, so the method
fails. However, progress may nevertheless be made by
considering the result from the case of Jurkat T* induced
by low FasL. The strategy is to transform the conditions
of that case into equivalent cell-specific parameter
conditions. For example, the Jurkat T* cell mutes the
reactions involving the action of Casp3* on other
molecules. This effect may be achieved in principle by
increasing [XIAP]0 and hence the inhibition of Casp3*,
w h i c ht u r n so u tt ob ei n s u f f i c i e n ta sar e s u l to ft h es t r o n g
positive feedback between Casp8 and Casp3. Therefore,
it is further necessary to decrease the rate at which Casp8
is activated. This may be controlled at the DISC module,
so accordingly decrease [FasR]0 (for the dependence, see
Figure 2a).
At the assumed rate parameters, however, the changes in
[XIAP]0 and [FasR]0 required to achieve type II apoptosis
are rather dramatic. Note though that the dissociation
rates k-4 and k-6 of Casp3*-XIAP and Casp8*-BAR,
respectively, as estimated from Eissing et al. [65] are
suspiciously large; if the estimate k-4 = k-6 =1 0
-3 s
-1 is
taken instead, more consistently with, e.g., [66, 70, 71],
t h e nt h ec h a n g e sr e q u i r e da r en om o r et h a na no r d e ro f
magnitude. Specifically, starting with Jurkat T para-
meters, increasing [XIAP]0 from 20 to 200 nM, and
decreasing [FasR]0 from 10 to 1 nM gives a cell type for
which the intrinsic pathway is significant even under
high FasL induction. The sensitivity regression analysis
f o rt h i sc e l li ss h o w ni nF i g u r e4 h( r
2 = 0.9264), which
displays significant components corresponding to the
intrinsic subnetwork, notably at k13.T h ei n f l u e n c eo ft h e
intrinsic pathway demonstrated by the comparison of
time courses in Figure 7 shows a significant delay of
caspase activation upon disabling the pathway coupling
through tBid. In comparison, control results for the HeLa
and Jurkat T cells show no such dependence (not
shown).
Perhaps in light of this result, an alternative interpreta-
tion of the fact that the modified regressions produced
poor fits occurs due to type II transitions requiring large
changes that the local character of the linear regression
cannot capture. This is consistent with the changes that
Hua et al. and Okazaki et al. [70, 71] report to effect
transitions in their models (without caspase feedback),
where, effectively, [Casp8]0 was modified by a similar
amount. As a final note, changes of this magnitude are
likely reasonable given the inherent variability experi-
mentally observed (see, e.g., [83]).
Activation thresholds and stability
It should be noted that the model in its present
formulation is unstable, even to transient signals, as
Figure 7 suggests. However, some notion of stability may
nevertheless be achieved by considering activation times.
This is shown for HeLa, Jurkat T, and Jurkat T* cells in
Figure 8.
Consider first the case of receptor-mediated apoptosis, i.
e., by FasL induction. For HeLa and Jurkat T cells, the
peak activation is essentially constant (Figure 8a) with
[FasL]0, in accordance with the observation from the
regression analyses that the peak activation is relatively
insensitive. However, the activation time (Figure 8b)
varies significantly, showing first a sharp decrease with
[FasL]0 for low [FasL]0, then a gradual leveling-off as
[FasL]0 increases thereafter. Clearly, this latter portion
may be interpreted as the cell undergoing apoptosis in a
saturated manner, in which further increase of the death
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Figure 7
Type II prediction time course.T i m ec o u r s eo fc a s p a s e -
3 activation ([Casp3*]) for the type II apoptosis cell
prediction parameters (k-4 = k-6 =1 0
-3 s
-1,[ X I A P ] 0 = 200
nM, [FasR]0 = 1 nM) induced by [FasL]0 = 2 nM. The solid line
gives the time course of the full model, while the dashed line
gives the time course with k7 = 0 (i.e., no Bid truncation,
hence no extrinsic-intrinsic coupling). Note the significant
delay in caspase activation.
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(page number not for citation purposes)signal no longer affects the response time. Analogously,
the initial drop appears to define a transition region,
wherein the cell switches from slow to fast apoptotic
dynamics over a narrow range of the death signal input;
this is indicative of some threshold-like behavior.
Although this is not bistability, a sense of the existence
of both low and high apoptotic states is nevertheless
furnished, which, furthermore, may be made precise by
introducing an artificial cutoff on the activation time to
discount activations which take too long to occur. The
case of the Jurkat T* cell is similar, though now the peak
activation does show nontrivial variation with [FasL]0.
However, the peak activation remains uniformly rather
high which questions biological significance.
Corresponding data for mitochondrial apoptosis (vari-
able [tBid]0 with [FasL]0 =0 )a r es h o w ni nF i g u r e8 c ,d .
The cases for the HeLa and Jurkat T cells are similar as the
receptor-mediated case; however, the Jurkat T* cell
appears to exhibit bistability (Figure 8c). For low FasL
(approximately [FasL]0 <1 0
-2 nM), the peak activation
stays low (near zero), whereas for high FasL ([FasL]0 >
1 nM), the peak activation reaches a high state around
145 nM. Intermediate concentrations define a transition
r e g i o nw h e r et h ec e l lm a yb ei n t e r p r e t e dt os w i t c hf r o m
life to death.
The present data was computed with a constant input for
the receptor-mediated case and an exponentially decay-
ing (i.e., transient) input for the mitochondrial case
(since tBid has a constitutive degradation rate in the
model). Interestingly, instituting a transient FasL signal,
with estimated degradation rate μFasL =1 0
-5 s
-1,g i v e sn o
discernable change to the receptor-mediated data, while
setting μtBid = 0 degrades the quality of the bistability
result of the Jurkat T* case for mitochondrial apoptosis
(not shown). This affords some insight into why the
noted bistability is observed: by virtue of the delay of
apoptosis incurred by the intrinsic pathway through the
necessary activation of the mitochondrial apoptogenic
factors and the assembly of the apoptosome (compare
Figures 8b and 8d), the intrinsic pathway is able to better
filter out transient signals.
With regard to stability, perhaps this implies that further
models of apoptosis should be careful to include
potentially important regulators such as cFLIP, which
inhibits DISC and hence imposes a delay on Casp8
activation [70, 71]. Moreover, it may likewise be prudent
to expand in full any series of activations occuring
sequentially; an example might be the interactions
between Bid and Bax to form the MAC, which currently
is not mechanistically understood and consequently may
be inappropriately abstracted; although in defense of the
abstraction, it is experimentally suggested that compo-
nent levels (such as Apaf-1 or Casp9) may determine
how quickly some cells die [83]. Finally, in this view, the
steady-state abstractions presented are actually quite
unsuitable for the purposes of model stability; however,
modulation of the given abstracted dynamics by appro-
priate time-dependent functions (e.g., by an appropriate
Heaviside function) may suffice.
Conclusion
This study has presented a methodological construction
of a straightforward and informative mathematical
model of apoptosis. This was done by combining both
the extrinsic and intrinsic pathways through the imple-
mentation of functional modules and subnetworks
motivated by previous models and findings [65-67,
69-71, 74, 75]. The subnetworks, responsible for the
activation of Casp3 and ultimately apoptosis, included
descriptions of both the extrinsic and intrinsic pathways
as well as the coupling between them. Modularization of
the oligomerization kinetics of the DISC, MAC, and
apoptosome were achieved through the implementation
of steady-state abstraction techniques.
Sensitivity analysis by linear regression was used to
identify key components of the apoptotic network under
various cell conditions. This allowed for the formulation
Figure 8
Peak caspase-3 activations and activation times.P e a k
caspase-3 activations and activations times for HeLa (dots),
Jurkat T (circles), and Jurkat T*(asterisks) cells under
receptor-mediated apoptosis (variable [FasL]0)a n d
mitochondrial apoptosis (variable [tBid]0 with [FasL]0 =0 ) .
(a) Peak activations for receptor-mediated apoptosis. (b)
Activation times for receptor-mediated apoptosis. (c) Peak
activations for mitochondrial apoptosis. (d) Activation times
for mitochondrial apoptosis.
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(page number not for citation purposes)of reduced models to capture only the essential
dynamics of the system. Importantly, these reductions
allowed the extraction of biological insight and helped
clarify the roles of specific molecular components. For
example, the model predicts for the parameter regimes
considered that Casp9* contributes to the activation of
Casp3 by direct catalytic activation rather than through
sequestration of their common inhibitor XIAP. Further-
more, the reduced models validated many previous
findings, including the critical role of XIAP and the
shared-inhibitor motif in mediating apoptosis [66,
84-87], as well as the transition from type I to type II
apoptosis as the induction of the extrinsic pathway is
decreased [70, 71]. Finally, the analysis revealed the
variety of modes through which caspase activation can
be achieved. In the cases considered, caspase activation
was observed to occur 1) solely through the extrinsic
pathway 2) solely through the intrinsic pathway 3)
through the extrinsic triggering the intrinsic pathway and
4) through the intrinsic triggering the extrinsic pathway.
Whether cells employ all of these modes is an interesting
experimental question, with possibly profound biologi-
cal significance.
The results of the regression analyses were also used to
predict cell parameters (i.e., initial concentrations) that
would elicit type II apoptosis, even under high FasL
induction, without having to use the Jurkat T* model of
Hua et al. and Okazaki et al. [70, 71], which omits
important caspase feedback interactions [65, 66]. This
adheres to the notion of highly conserving the apoptosis
pathway [1, 6, 15], and in principle, achieving both type
I and type II apoptosis using the same network.
Naturally, the type II cell prediction invites experimental
investigation.
Furthermore, remarks on caspase activation thresholds
and stability were given. The critical element in achieving
bistability in the system (at least to transient signals)
appears to be related to whether sufficient delays are
included. In particular, this implies the importance of
modeling regulators, especially inhibitors, of the system,
as well as the correct dynamical description of complex
formation. Specifically, for this latter point, the present
formulation neglects the time dependence of the
oligomerization rate and assumes that the formation of
a given final complex proceeds without delay. This,
however, does not reflect actual dynamics; for example,
the model of apoptosome assembly by Nakabayashi and
Sasaki [75] at the parameter values considered in this
study exhibits a characteristic time delay on the order of
100 min. A simple improvement is the delayed initiation
of the present approximation by an appropriate time. A
general theory of oligomerization that gives such a time
would be particularly useful. Finally, of special interest is
whether the incorporation of such delays can recover the
expected type II behavior of the Jurkat T cell while
maintaining the type I behavior of the HeLa cell.
Future directions for model refinement include more
sophisticated treatment of oligomerization kinetics as
described. A more comprehensive procedure for model
reduction would also be helpful. The current method of
sensitivity analysis is unable to eliminate reactions near
saturation; however these cases should intuitively be
treatable analytically. Moreover, the implementation of a
faithful model exhibiting bistability is of primary
biological interest as this would allow the formal
definition and investigation of a point of no return in
apoptosis. Furthermore, it may be profitable to adapt
and apply the model to other cell types, e.g., mature
neurons, which have repressed Apaf-1 expression and
hence apoptosome formation [88, 89]. Extending the
presented work to model apoptosis at a cell population
level may predict key mechanisms; and perhaps, prove
fruitful for understanding drug sensitivity in various cell
lines.
The model thus presented serves as a guide for future
theoretical and experimental work in analyzing apopto-
sis and achieves progress toward a full model of this
important biological process.
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